中國(guó)蘇州和美國(guó)馬里蘭州羅克維爾市2022年4月28日 /美通社/ -- 致力于在腫瘤、乙肝及與衰老相關(guān)疾病等治療領(lǐng)域開發(fā)創(chuàng)新藥物的領(lǐng)先的生物醫(yī)藥企業(yè)——亞盛醫(yī)藥(6855.HK)今日宣布,公司共七項(xiàng)臨床研究入選2022年美國(guó)臨床腫瘤學(xué)會(huì)(ASCO)年會(huì),涉及第三代酪氨酸激酶抑制劑(TKI)奧雷巴替尼(HQP1351)、Bcl-2抑制劑APG-2575、MDM2-p53抑制劑APG-115、ALK抑制劑APG-2449和Bcl-2/Bcl-xL抑制劑APG-1252 五個(gè)原研品種。
一年一度的ASCO年會(huì)是全球腫瘤領(lǐng)域最重要的、最為權(quán)威的學(xué)術(shù)交流盛會(huì),將展示當(dāng)前國(guó)際最前沿的臨床腫瘤學(xué)科研成果和腫瘤治療技術(shù)。本屆ASCO年會(huì)將于6月3日至7日(美國(guó)當(dāng)?shù)貢r(shí)間)在芝加哥McCormick會(huì)議中心以線上線下形式舉辦。
亞盛醫(yī)藥首席醫(yī)學(xué)官翟一帆表示:"這將是亞盛醫(yī)藥連續(xù)第五年亮相ASCO,很高興能展示我們的多項(xiàng)臨床進(jìn)展,進(jìn)一步體現(xiàn)了公司的全球化創(chuàng)新與開發(fā)實(shí)力。此次除了細(xì)胞凋亡品種APG-2575、APG-115相關(guān)試驗(yàn)數(shù)據(jù)的進(jìn)一步展示,有望成為國(guó)產(chǎn)首個(gè)第三代ALK抑制劑APG-2449的臨床數(shù)據(jù)將首次披露,同時(shí)奧雷巴替尼(HQP1351)在治療胃腸間質(zhì)瘤(GIST)方面的臨床進(jìn)展也將首次公布。我們期待在后續(xù)會(huì)議期間與大家分享相關(guān)的更詳實(shí)的數(shù)據(jù)。未來,亞盛將進(jìn)一步加速推進(jìn)全球臨床開發(fā),早日為患者帶來更多治療選擇。"
亞盛醫(yī)藥將在本屆ASCO年會(huì)展示的七項(xiàng)最新臨床試驗(yàn)進(jìn)展包括:
奧雷巴替尼(HQP1351):
Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).
奧雷巴替尼(HQP1351)在酪氨酸激酶抑制劑(TKI)耐藥的琥珀酸脫氫酶缺陷型胃腸間質(zhì)瘤(SDH-deficient GIST)患者中顯示良好的抗腫瘤活性
APG-2575:
A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).
新型BCL-2抑制劑(BCL-2i)APG-2575治療復(fù)發(fā)/難治性慢性淋巴細(xì)胞白血病/小淋巴細(xì)胞淋巴瘤(R/R CLL/SLL)患者的Ib/II期臨床研究
Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER?) breast cancer or advanced solid tumors.
一項(xiàng)旨在評(píng)估BCL-2抑制劑APG-2575單藥或聯(lián)合周期蛋白依賴性激酶4/6(CDK4/6)抑制劑治療雌激素受體陽(yáng)性(ER+)乳腺癌和晚期實(shí)體瘤患者的安全性和耐受性的Ib/II期臨床研究
APG-115:
Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
新型MDM2-p53抑制劑APG-115聯(lián)合帕博利珠單抗治療成人及兒童實(shí)體瘤患者的最新II期臨床數(shù)據(jù)
APG-2449:
First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1 non-small-cell lung cancer (NSCLC) or mesothelioma.
新型FAK抑制劑和第三代ALK/ ROS1酪氨酸激酶抑制劑(TKI)APG-2449治療對(duì)二代TKI耐藥的ALK/ROS1非小細(xì)胞肺癌(NSCLC)和間皮瘤患者的首次人體I期試驗(yàn)數(shù)據(jù)
APG-1252:
Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non-small-cell lung cancer (NSCLC).
APG-1252聯(lián)合奧希替尼治療攜帶EGFR突變的非小細(xì)胞肺癌(NSCLC)患者的最新臨床數(shù)據(jù)
First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).
APG-1252聯(lián)合紫杉醇治療復(fù)發(fā)/難治性小細(xì)胞肺癌(R/R SCLC)患者的首次人體試驗(yàn)